Solid investor interest as Ambit raises new funds for quizartinib-led pipeline
This article was originally published in Scrip
Executive Summary
Ambit Biosciences closed the first $25 million tranche of a $50 million preferred stock financing to support late-stage development of its lead drug candidate quizartinib (AC220), as the private San Diego-based company prepares its Phase II data in the treatment of acute myeloid leukemia (AML) for presentation at the American Society of Hematology (ASH) annual meeting.